Advanced Oncotherapy UK assembly and testing site agreement

Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announced today that is has signed a lease with the UK Government’s Science and Technology Facilities Council to establish a UK testing and assembly site for its next generation proton accelerator, “LIGHT”, at the STFC Daresbury Laboratory in Cheshire, home to the UK’s Accelerator Science and Technology Centre.

The STFC facility will become the testing and assembly site of the Company’s first fully operational LIGHT system. Building work will now begin to prepare the site to receive the LIGHT system components from June 2018 onwards. This site will then be used to assemble the first LIGHT system capable of accelerating protons to the full 230 MeV required for effective proton therapy treatment of deep seated tumours. The site will be used to complete the verification and validation of the LIGHT system ahead of its submission for regulatory approval, before it is relocated and installed at the first commercial site in Harley Street. As outlined to investors in March 2017, the Company is targeting first patient treatment at Harley Street for H2 2020.

The Company will maintain its testing facility at CERN, Geneva where it continues to advance its LIGHT system technological development.

Advantages of the STFC Daresbury facility

The agreement with STFC provides access to an established and certified facility supported by a strong reputation for the research, development and operation of future particle accelerators. The use of an existing high-tech site will provide advantages in both cost and timescale, but also provides additional risk diversification with an additional production facility option.

STFC was an active partner in the initial installation of the Large Hadron Collider at CERN in Geneva, and further upgrades thereof. The Daresbury Laboratory is home to the Accelerator Science and Technology Centre (ASTeC) and Cockcroft Institute of Accelerator Science and Technology. It houses teams of scientists from STFC and the Universities of Lancaster, Liverpool, Manchester and Strathclyde carrying out research in accelerator science with applications across a range of disciplines.

Production manufacturing options

The Company is aiming at further streamlining the LIGHT system production process. AVO and Thales are in discussion to assess their options for a future collaboration on the industrialization of the machine and supply chain strategy. Also, the opportunity exists to scale up the manufacturing infrastructure through the set-up of additional production sites.

Commenting, Nicolas Serandour, CEO of Advanced Oncotherapy Plc, said: “Our agreement with the Science and Technology Facilities Council is an important step towards the construction of our first fully operational LIGHT system, to be constructed within the UK’s accelerator research and innovation hub. Having a facility with established infrastructure, a certified site and a huge wealth of shared knowledge in the area of accelerators allows us to quickly move forward the construction of the first commercial LIGHT system in a cost-effective way.

“Our Geneva testing facility will see the acceleration of protons to energies capable of treating superficial tumours by the end of Q3 this year and, using the detailed results from that process, we will construct our first fully operational system at the STFC Daresbury Laboratory. I am particularly pleased that a technology that will be available first in the very heart of London’s renowned Harley Street medical district will be constructed in the heart of the UK’s foremost centre for advanced particle acceleration innovation.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Advanced Oncotherapy Plc

    More articles like this

    Hardman & Co

    ADVANCED ONCOTHERAPY Nearing the end goal

    AVO’s goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. 2018 was characterised by the achievement of a number of technical milestones,

    Hardman & Co

    Advanced Oncotherapy Commercialising a breakthrough technology

    Advanced Oncotherapy (LON:AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. 2018 was characterised by achievement of a number of technical milestones,

    Hardman & Co

    Advanced Oncotherapy Preparing for commercialisation

    Advanced Oncotherapy (LON:AVO) goal is to deliver an affordable and novel proton beam therapy system (PBT), based on state-of-the-art technology developed originally at the world-renowned CERN. 2018 was characterised by the achievement of a number of

    Hardman & Co

    Advanced Oncotherapy Important regulatory milestone: ISO approval

    Advanced Oncotherapy (LON:AVO)  goal is to deliver an affordable and novel proton therapy (PT) system, based on state-of-the-art technology developed originally at the CERN. Achievement of major technical milestones has boosted confidence, and the group remains

    Hardman & Co

    Advanced Oncotherapy Four components integrated

    Advanced Oncotherapy (LON:AVO)  goal is to deliver an affordable and novel proton therapy system (PT), based on state-of-the-art technology developed originally at the world-renowned CERN. Achievement of major technical milestones has boosted confidence greatly, and the

    Advanced Oncotherapy Plc

    University Hospitals hitting mark with proton therapy

    While some proton therapy centres across the country have reportedly struggled to stay profitable, officials at University Hospitals say they’ve found the “sweet spot” two years after the Cleveland-based health system opened its own $30 million

    Advanced Oncotherapy Plc

    Advanced Oncotherapy a Significant Year

    Nicolas Serandour, CEO of Advanced Oncotherapy, said: “The technological development of our LIGHT system remains on-track and we continue to proceed with a significantly reduced overall technology risk profile. Similarly work at Harley Street remains on

    Advanced Oncotherapy Plc

    90-tonne cancer-fighting cyclotron arrives in London

    A 90-tonne piece of cancer-fighting equipment that will improve the lives of hundreds of cancer patients every year has been carefully lowered into place in its new home. The cyclotron is the size of a family

    Advanced Oncotherapy Plc

    CERN Technology Next Generation Cancer Treatment

    STFC and Advanced Oncotherapy (LON:AVO) are collaborating in the construction of a proton therapy assembly and test facility at STFC’s Daresbury Laboratory, that will build on the technology at the heart of the Large Hadron Collider

    Advanced Oncotherapy Plc

    Proton Beam therapy to come to Isarel

    The deputy Health Minister Yaakov Litzman has ordered his ministry to finalise plans to establish a Proton Beam Therapy center in Israel. The announcement came after Litzman returned to Israel this week from a visit to

    Advanced Oncotherapy Plc

    Radiation for Mesothelioma: Could Proton Therapy Be the Answer?

    Researchers at the Maryland Proton Therapy Treatment Center say that a highly-targeted version of proton beam radiation could be the future of radiotherapy for malignant plural mesothelioma. Advanced Oncotherapy (LON:AVO), is developing a unique, fully integrated,

    Advanced Oncotherapy Plc

    Professor Stephen Myers: Beams of Life

    Proton therapy is a new way of beating cancer, with fewer side effects than conventional radiation treatments, explains Stephen Myers a pioneering nuclear medicine scientist & ADAM Executive Chairman at Advanced Oncotherapy PLC (LON:AVO)   Advanced Oncotherapy

    Advanced Oncotherapy Plc

    Curing Cancer with Proton Beams

      Particle accelerators do more than just particle physics research. Suzie Sheehy takes a look at the history and promise of proton therapy: using particle accelerators to fight cancer. The discovery of X-rays in 1895 was

    Advanced Oncotherapy Plc

    Advanced Oncotherapy PLC Update on Distribution Agreement Payment

    Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that further to the Company’s announcement of 3 April 2018, the Company has received from Yantai Cipu, through its affiliated entity Liquid